Cargando…
Neuroblastic Tumours in Children: Outcome from a Referral Centre in India
BACKGROUND: There is a paucity of uniform literature on the outcome of children with neuroblastic tumours from developing countries. This study aims to present the outcome in children having neuroblastic tumours. MATERIALS AND METHODS: We retrospectively reviewed patients with neuroblastic tumours f...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117020/ https://www.ncbi.nlm.nih.gov/pubmed/36722567 http://dx.doi.org/10.4103/ajps.ajps_152_21 |
_version_ | 1785028544477265920 |
---|---|
author | Kumar, Basant Yadav, Rajanikant Upadhyaya, Vijai D Mishra, Ashwani Yousuf, Mishra, Prabhakar Lal, Punita |
author_facet | Kumar, Basant Yadav, Rajanikant Upadhyaya, Vijai D Mishra, Ashwani Yousuf, Mishra, Prabhakar Lal, Punita |
author_sort | Kumar, Basant |
collection | PubMed |
description | BACKGROUND: There is a paucity of uniform literature on the outcome of children with neuroblastic tumours from developing countries. This study aims to present the outcome in children having neuroblastic tumours. MATERIALS AND METHODS: We retrospectively reviewed patients with neuroblastic tumours from January 2014 to March 2020. Data analysed were pertaining to the age, sex, presentation, site, stage, diagnostic evaluation performed, management and follow-up results, etc., The final outcomes were assessed as complete response; partial response (PR); no response (NR) and progressive disease. International Neuroblastoma Risk Group staging was used and patients were categorised on the basis of age, site and stage of tumour. Overall survival (OS) was calculated from the date of diagnosis to the date of last follow-up and event for OS was death. RESULTS: Forty-seven patients were included with median age of 60 months (ranges of 2–180; mean = 61.87 ± 47.56). About 72.3% (n = 34) patients were males. Out of total, 6.4% (n = 3), 53.2% (n = 25) and 38.3% (n = 18) were in stage L1, L2 and M, respectively, whereas 2.1% (n = 1) patients were in stage MS. Surgery was performed in 25 (53.19%) patients, but gross total excision was achieved in 48.90% (n = 23) patients. Onlu 10.60% (n = 5) patients were referred, whereas 14.89% (n = 7) patients reported recurrences. Mean and median follow-up time of the patients was 24.64 ± 16.04 and 18 months (range: 3–60 months). Out of total, 53.2% (n = 25) and 29.8% (n = 14) patients had complete and PRs, respectively, whereas 17% (n = 8) patients had NR. Out of the total 47 patients, 8 (17%) achieved events (deaths), whereas the rest, 39 (83%) patients, were censored. Mean event-free OS time was 50.04 months. CONCLUSION: There was a significant difference in patient deaths in recurrence and non-recurred patients (4/7, 57.1% vs. 4/40/, 10%, P = 0.011). Survival time was significantly higher in patients with stages L1-L2 as compared to Stage 4. Stage and age were found predictors of survival. |
format | Online Article Text |
id | pubmed-10117020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-101170202023-04-21 Neuroblastic Tumours in Children: Outcome from a Referral Centre in India Kumar, Basant Yadav, Rajanikant Upadhyaya, Vijai D Mishra, Ashwani Yousuf, Mishra, Prabhakar Lal, Punita Afr J Paediatr Surg Original Article BACKGROUND: There is a paucity of uniform literature on the outcome of children with neuroblastic tumours from developing countries. This study aims to present the outcome in children having neuroblastic tumours. MATERIALS AND METHODS: We retrospectively reviewed patients with neuroblastic tumours from January 2014 to March 2020. Data analysed were pertaining to the age, sex, presentation, site, stage, diagnostic evaluation performed, management and follow-up results, etc., The final outcomes were assessed as complete response; partial response (PR); no response (NR) and progressive disease. International Neuroblastoma Risk Group staging was used and patients were categorised on the basis of age, site and stage of tumour. Overall survival (OS) was calculated from the date of diagnosis to the date of last follow-up and event for OS was death. RESULTS: Forty-seven patients were included with median age of 60 months (ranges of 2–180; mean = 61.87 ± 47.56). About 72.3% (n = 34) patients were males. Out of total, 6.4% (n = 3), 53.2% (n = 25) and 38.3% (n = 18) were in stage L1, L2 and M, respectively, whereas 2.1% (n = 1) patients were in stage MS. Surgery was performed in 25 (53.19%) patients, but gross total excision was achieved in 48.90% (n = 23) patients. Onlu 10.60% (n = 5) patients were referred, whereas 14.89% (n = 7) patients reported recurrences. Mean and median follow-up time of the patients was 24.64 ± 16.04 and 18 months (range: 3–60 months). Out of total, 53.2% (n = 25) and 29.8% (n = 14) patients had complete and PRs, respectively, whereas 17% (n = 8) patients had NR. Out of the total 47 patients, 8 (17%) achieved events (deaths), whereas the rest, 39 (83%) patients, were censored. Mean event-free OS time was 50.04 months. CONCLUSION: There was a significant difference in patient deaths in recurrence and non-recurred patients (4/7, 57.1% vs. 4/40/, 10%, P = 0.011). Survival time was significantly higher in patients with stages L1-L2 as compared to Stage 4. Stage and age were found predictors of survival. Wolters Kluwer - Medknow 2023 2023-01-31 /pmc/articles/PMC10117020/ /pubmed/36722567 http://dx.doi.org/10.4103/ajps.ajps_152_21 Text en Copyright: © 2023 African Journal of Paediatric Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Kumar, Basant Yadav, Rajanikant Upadhyaya, Vijai D Mishra, Ashwani Yousuf, Mishra, Prabhakar Lal, Punita Neuroblastic Tumours in Children: Outcome from a Referral Centre in India |
title | Neuroblastic Tumours in Children: Outcome from a Referral Centre in India |
title_full | Neuroblastic Tumours in Children: Outcome from a Referral Centre in India |
title_fullStr | Neuroblastic Tumours in Children: Outcome from a Referral Centre in India |
title_full_unstemmed | Neuroblastic Tumours in Children: Outcome from a Referral Centre in India |
title_short | Neuroblastic Tumours in Children: Outcome from a Referral Centre in India |
title_sort | neuroblastic tumours in children: outcome from a referral centre in india |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117020/ https://www.ncbi.nlm.nih.gov/pubmed/36722567 http://dx.doi.org/10.4103/ajps.ajps_152_21 |
work_keys_str_mv | AT kumarbasant neuroblastictumoursinchildrenoutcomefromareferralcentreinindia AT yadavrajanikant neuroblastictumoursinchildrenoutcomefromareferralcentreinindia AT upadhyayavijaid neuroblastictumoursinchildrenoutcomefromareferralcentreinindia AT mishraashwani neuroblastictumoursinchildrenoutcomefromareferralcentreinindia AT yousuf neuroblastictumoursinchildrenoutcomefromareferralcentreinindia AT mishraprabhakar neuroblastictumoursinchildrenoutcomefromareferralcentreinindia AT lalpunita neuroblastictumoursinchildrenoutcomefromareferralcentreinindia |